contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


redeye-optomed-q2-soft-sales-and-important-quarters-ahead

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Optomed är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling av specialiserade ögonkameror. Utveckling sker av både hård- och mjukvara som vidaresäljs under olika varumärken. Verksamhet innehas på global nivå, med störst närvaro inom den nordiska marknaden. Kunderna består av forskningsinstitut samt sjukhus. Huvudkontoret ligger i Oulu.

Kyllä tuo Optomed näyttää olevan WHO:n hovitoimittaja. Aika muikea referenssi yritys ja kohtuullisen globaali sellainen

Tässäkin WHO:n rahoittamassa Kirgisian 3-vuotisessa projektissa käytettiin nähtävästi Optomedin kameraa.                   who.int              Marking a milestone in diabetes care in Kyrgyzstan    The WHO–World Diabetes Foundation project in Kyrgyzstan, launched to address the country’s rising burden of diabetes and its complications, concludes its 3-year phase having trained over 200 health-care workers and 119 nurses. The initiative has...

Ei kai ole poikkeuksellista, että yksilötason osaamista vaativissa hommissa pidetään hakua päällä, vaikkei kriittistä tyhjää aukkoa olisikaan täytettävänä. Varsinkaan linkkarin kaltaisissa itsekeh… verkostoitumisalustoissa. Low risk, high reward.

Eikös näitä nyt ole jokainen yli 5 hengen myyntiorganisaatio pullollaan. Myyntijohtajia sitten vähemmän.

Vai olisiko ihan uusi hakusessa ”vanhojen” lisäksi?

Kuka oli edellinen myyntipäällikkö ja miksi vaihtoon?

Kävin ajan kuluksi vähän surffailemassa Opton USA:n linkkarisivuilla ja siellä oli myyntipäällikön paikka auki (jälleen yksi positiivinen signaali lisää). Onko kenelläkään mitään ymmärrystä, kuinka isolla myyntiorkesterilla Yhdysvalloissa operoidaan

Optomed

Redeye provides an update following Optomed’s Q2 report. Although sales and EBIT came in lower than anticipated, we argue that the investment case remains intact. We highlight upcoming reports...

<div class="mfn-body"><p>Redeye provides an update following Optomed’s Q2 report. Although sales and EBIT came in lower than anticipated, we argue that the investment case remains intact. We highlight upcoming reports that may potentially show sales related to the US rollout of Aurora AEYE. Furthermore, we have made only minor estimate changes, leaving the fair value range unchanged.</p><p><a rel="noopener" href="https://www.redeye.se/research/1028439/optomed-q2-soft-sales-and-important-quarters-ahead?utm_source=MFN&amp;utm_medium=pmcour">Read more and download the Research Update.</a><br>&nbsp;<br>Follow companies at Redeye to receive the latest equity research within Life Science and Technology.<br>&nbsp;<br>This is a press release from Redeye - Research Powered Investment Banking. <a rel="noopener" href="https://www.redeye.se/">www.redeye.se/</a></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/8f8ad72d-ea0e-4cf1-9a95-1069c5c00d0d/optomed-q2-soft-sales-and-important-quarters-ahead.pdf" class="mfn-generated mfn-primary">Optomed Q2 - Soft sales and important quarters ahead</a></p></div>

Beställ vårt nyhetsbrev — inget användarkonto krävs!